NASDAQ:TECH - Bio-Techne Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$152.97 +1.35 (+0.89 %)
(As of 05/20/2018 03:46 PM ET)
Previous Close$152.97
Today's Range$151.57 - $153.87
52-Week Range$107.55 - $154.56
Volume224,228 shs
Average Volume185,614 shs
Market Capitalization$5.75 billion
P/E Ratio39.43
Dividend Yield0.84%
Beta0.72

About Bio-Techne (NASDAQ:TECH)

Bio-Techne logoBio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells biotechnology reagents, instruments, and clinical diagnostic controls worldwide. It operates through three segments: Biotechnology, Protein Platforms, and Diagnostics. The Biotechnology segment offers native and recombinant proteins, monoclonal and polyclonal antibodies, immunoassays, biologically active chemical compounds, and in situ genomic hybridization assays for the research and clinical diagnostics markets. It also provides various products, which serves as predictive biomarkers and therapeutic targets for various human diseases and conditions, including cancer, autoimmunity, diabetes, hypertension, obesity, inflammation, neurological disorders, and kidney failure. The Protein Platforms segment develops, manufactures, and sells tools, such as Biologics platform that enables researchers interrogate protein purity and identify contaminants during the development and production of biologics; Simple Western platform for protein analysis and identification; SimplePlex platform, an enzyme-linked immunosorbent assay for use in research and clinical diagnostics; and Single Cell Western platform to elucidate the properties of individual cells to understand cell behavior. The Diagnostics segment offers controls and calibrators for hematology clinical instruments; blood chemistry and blood gas quality controls, diagnostic immunoassays, and other bulk and custom reagents for the in vitro diagnostic market; bulk purified proteins, enzymes, disease-state plasmas, infectious disease antigens, and processed serums to the clinical diagnostic industry; and Paratest, a novel and convenient stool collection and test device for the veterinary market. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.

Receive TECH News and Ratings via Email

Sign-up to receive the latest news and ratings for TECH and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryLife Sciences Tools & Services
SectorMedical
SymbolNASDAQ:TECH
CUSIP87837710
Phone612-379-8854

Debt

Debt-to-Equity Ratio0.37
Current Ratio5.55
Quick Ratio4.30

Price-To-Earnings

Trailing P/E Ratio39.43
Forward P/E Ratio37.77
P/E Growth2.52

Sales & Book Value

Annual Sales$563 million
Price / Sales10.21
Cash Flow$5.0468 per share
Price / Cash30.31
Book Value$28.17 per share
Price / Book5.43

Profitability

EPS (Most Recent Fiscal Year)$3.42
Net Income$76.08 million
Net Margins18.29%
Return on Equity14.75%
Return on Assets9.35%

Miscellaneous

Employees1,800
Outstanding Shares37,570,000

Bio-Techne (NASDAQ:TECH) Frequently Asked Questions

What is Bio-Techne's stock symbol?

Bio-Techne trades on the NASDAQ under the ticker symbol "TECH."

How often does Bio-Techne pay dividends? What is the dividend yield for Bio-Techne?

Bio-Techne announced a quarterly dividend on Thursday, May 3rd. Stockholders of record on Monday, May 14th will be given a dividend of $0.32 per share on Friday, May 25th. This represents a $1.28 annualized dividend and a dividend yield of 0.84%. The ex-dividend date is Friday, May 11th. View Bio-Techne's Dividend History.

How were Bio-Techne's earnings last quarter?

Bio-Techne (NASDAQ:TECH) posted its earnings results on Wednesday, May, 2nd. The biotechnology company reported $1.21 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.14 by $0.07. The biotechnology company had revenue of $164 million for the quarter, compared to the consensus estimate of $163.43 million. Bio-Techne had a net margin of 18.29% and a return on equity of 14.75%. The business's quarterly revenue was up 13.9% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.97 earnings per share. View Bio-Techne's Earnings History.

When is Bio-Techne's next earnings date?

Bio-Techne is scheduled to release their next quarterly earnings announcement on Tuesday, August, 14th 2018. View Earnings Estimates for Bio-Techne.

What price target have analysts set for TECH?

6 brokers have issued twelve-month price targets for Bio-Techne's stock. Their forecasts range from $115.00 to $165.00. On average, they anticipate Bio-Techne's share price to reach $151.40 in the next year. View Analyst Ratings for Bio-Techne.

Who are some of Bio-Techne's key competitors?

Who are Bio-Techne's key executives?

Bio-Techne's management team includes the folowing people:
  • Mr. Charles R. Kummeth, Pres, CEO & Director (Age 58)
  • Mr. James T. Hippel, Sr. VP of Fin., CFO & Principal Accounting Officer (Age 47)
  • Mr. N. David Eansor, Sr. VP of Biotechnology Division (Age 57)
  • Mr. Robert M. Gavin, Sr. VP of Protein Platforms Division (Age 50)
  • Mr. Kevin S. Gould, Sr. VP of Diagnostics Division (Age 52)

Has Bio-Techne been receiving favorable news coverage?

Media coverage about TECH stock has trended somewhat positive on Sunday, according to Accern Sentiment. Accern identifies positive and negative media coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Bio-Techne earned a media sentiment score of 0.18 on Accern's scale. They also assigned news articles about the biotechnology company an impact score of 45.27 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near future.

Who are Bio-Techne's major shareholders?

Bio-Techne's stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (9.83%), Atlanta Capital Management Co. L L C (5.11%), Neuberger Berman Group LLC (4.39%), Bamco Inc. NY (4.06%), Select Equity Group L.P. (1.75%) and Massachusetts Financial Services Co. MA (1.24%). Company insiders that own Bio-Techne stock include Charles A Dinarello, John L Higgins, Karen A Holbrook, Kevin S Gould, Robert V Baumgartner and Roger C Lucas. View Institutional Ownership Trends for Bio-Techne.

Which institutional investors are selling Bio-Techne stock?

TECH stock was sold by a variety of institutional investors in the last quarter, including Select Equity Group L.P., Citadel Advisors LLC, New York State Common Retirement Fund, Sei Investments Co., Neuberger Berman Group LLC, Segall Bryant & Hamill LLC, Public Employees Retirement Association of Colorado and Russell Investments Group Ltd.. Company insiders that have sold Bio-Techne company stock in the last year include Charles A Dinarello, Karen A Holbrook, Robert V Baumgartner and Roger C Lucas. View Insider Buying and Selling for Bio-Techne.

Which institutional investors are buying Bio-Techne stock?

TECH stock was purchased by a variety of institutional investors in the last quarter, including Massachusetts Financial Services Co. MA, BlackRock Inc., Prudential Financial Inc., Schwab Charles Investment Management Inc., Asset Management One Co. Ltd., Citigroup Inc., Mariner LLC and JPMorgan Chase & Co.. View Insider Buying and Selling for Bio-Techne.

How do I buy shares of Bio-Techne?

Shares of TECH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Bio-Techne's stock price today?

One share of TECH stock can currently be purchased for approximately $152.97.

How big of a company is Bio-Techne?

Bio-Techne has a market capitalization of $5.75 billion and generates $563 million in revenue each year. The biotechnology company earns $76.08 million in net income (profit) each year or $3.42 on an earnings per share basis. Bio-Techne employs 1,800 workers across the globe.

How can I contact Bio-Techne?

Bio-Techne's mailing address is 614 MCKINLEY PLACE NE, MINNEAPOLIS MN, 55413. The biotechnology company can be reached via phone at 612-379-8854 or via email at [email protected]


MarketBeat Community Rating for Bio-Techne (TECH)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  176 (Vote Outperform)
Underperform Votes:  214 (Vote Underperform)
Total Votes:  390
MarketBeat's community ratings are surveys of what our community members think about Bio-Techne and other stocks. Vote "Outperform" if you believe TECH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TECH will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Bio-Techne (NASDAQ:TECH) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
6 Wall Street analysts have issued ratings and price targets for Bio-Techne in the last 12 months. Their average twelve-month price target is $151.40, suggesting that the stock has a possible downside of 1.03%. The high price target for TECH is $165.00 and the low price target for TECH is $115.00. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.832.832.712.50
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $151.40$148.75$144.25$130.00
Price Target Upside: 1.03% downside5.24% upside4.71% upside5.03% upside

Bio-Techne (NASDAQ:TECH) Consensus Price Target History

Price Target History for Bio-Techne (NASDAQ:TECH)

Bio-Techne (NASDAQ:TECH) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/3/2018Deutsche BankLower Price TargetBuy ➝ Buy$167.00 ➝ $165.00HighView Rating Details
5/3/2018Leerink SwannSet Price TargetBuy$151.00 ➝ $160.00LowView Rating Details
2/7/2018Craig HallumReiterated RatingBuy$140.00 ➝ $160.00MediumView Rating Details
2/7/2018Robert W. BairdBoost Price TargetOutperform ➝ Outperform$154.00 ➝ $157.00MediumView Rating Details
10/24/2017CitigroupReiterated RatingBuy$125.00 ➝ $115.00N/AView Rating Details
7/13/2017Wells FargoInitiated CoverageMarket Perform ➝ Market PerformLowView Rating Details
3/27/2017Janney Montgomery ScottDowngradeBuy ➝ NeutralHighView Rating Details
(Data available from 5/20/2016 forward)

Earnings

Bio-Techne (NASDAQ:TECH) Earnings History and Estimates Chart

Earnings by Quarter for Bio-Techne (NASDAQ:TECH)

Bio-Techne (NASDAQ:TECH) Earnings Estimates

2018 EPS Consensus Estimate: $3.92
2019 EPS Consensus Estimate: $4.37
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181$0.88$0.88$0.88
Q2 20182$0.84$0.88$0.86
Q3 20182$0.96$1.09$1.03
Q4 20182$1.09$1.21$1.15
Q1 20192$0.89$1.02$0.96
Q2 20192$0.92$1.11$1.02
Q3 20192$1.04$1.24$1.14
Q4 20192$1.18$1.33$1.26

Bio-Techne (NASDAQ TECH) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/6/2018$1.29N/AView Earnings Details
5/2/2018Q3 2018$1.14$1.21$163.43 million$164.00 millionViewN/AView Earnings Details
2/6/2018Q2 2018$0.92$1.02$145.93 million$154.15 millionViewListenView Earnings Details
10/31/2017Q1 2018$0.82$0.90$142.37 million$144.61 millionViewN/AView Earnings Details
8/8/2017Q4 2017$0.99$1.09$150.25 million$156.60 millionViewListenView Earnings Details
5/2/2017Q3 2017$0.93$0.97$142.83 million$144.04 millionViewListenView Earnings Details
2/7/2017Q217$0.85$0.81$134.74 million$131.80 millionViewListenView Earnings Details
10/31/2016Q117$0.79$0.84$127.47 million$130.60 millionViewListenView Earnings Details
8/17/2016Q416$0.96$0.92$129.23 million$134.80 millionViewListenView Earnings Details
5/3/2016Q316$0.89$1.01$122.65 million$131.00 millionViewN/AView Earnings Details
2/2/2016Q216$0.82$0.88$118.59 million$120.90 millionViewN/AView Earnings Details
10/28/2015Q1$0.85$0.79$116.91 million$12.40 millionViewListenView Earnings Details
8/6/2015Q415$0.86$0.87$116.85 million$117.70 millionViewN/AView Earnings Details
5/5/2015Q315$0.91$0.86$119.30 million$114.20 millionViewN/AView Earnings Details
2/3/2015Q215$0.86$0.89$112.73 million$111.90 millionViewN/AView Earnings Details
10/28/2014Q115$0.87$0.85$108.65 million$108.50 millionViewN/AView Earnings Details
8/11/2014Q414$0.85$0.88$91.80 million$92.50 millionViewN/AView Earnings Details
4/28/2014Q314$0.89$0.94$92.50 million$95.60 millionViewN/AView Earnings Details
2/4/2014Q214$0.80$0.75$84.79 million$84.00 millionViewN/AView Earnings Details
10/29/2013Q114$0.80$0.83$82.36 million$85.70 millionViewN/AView Earnings Details
8/6/2013Q4 2013$0.83$0.82$79.71 million$79.50 millionViewN/AView Earnings Details
4/30/2013Q3 2013$0.90$0.88$84.00 million$81.00 millionViewN/AView Earnings Details
2/5/2013Q2 2013$0.77$0.74$76.40 million$75.10 millionViewN/AView Earnings Details
10/23/2012$0.79$0.75ViewN/AView Earnings Details
7/31/2012$0.85$0.80ViewN/AView Earnings Details
5/1/2012$0.89$0.90ViewN/AView Earnings Details
1/31/2012$0.79$0.76ViewN/AView Earnings Details
10/25/2011$0.84$0.81ViewN/AView Earnings Details
8/2/2011$0.76$0.76ViewN/AView Earnings Details
5/3/2011$0.80$0.84ViewN/AView Earnings Details
2/1/2011$0.68$0.71ViewN/AView Earnings Details
10/26/2010Q1 2011$0.73$0.71ViewN/AView Earnings Details
8/3/2010Q4 2010$0.71$0.69ViewN/AView Earnings Details
5/4/2010Q3 2010$0.79$0.87ViewN/AView Earnings Details
2/2/2010Q2 2010$0.68$0.66ViewN/AView Earnings Details
10/28/2009Q1 2010$0.70$0.72ViewN/AView Earnings Details
8/4/2009Q4 2009$0.69$0.68ViewN/AView Earnings Details
4/28/2009Q3 2009$0.72$0.74ViewN/AView Earnings Details
2/3/2009Q2 2009$0.64$0.62ViewN/AView Earnings Details
10/22/2008Q1 2009$0.66$0.74ViewN/AView Earnings Details
8/5/2008Q4 2008$0.67$0.70ViewN/AView Earnings Details
4/29/2008Q3 2008$0.66$0.76ViewN/AView Earnings Details
1/29/2008Q2 2008$0.54$0.60ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Bio-Techne (NASDAQ:TECH) Dividend Information

Bio-Techne pays an annual dividend of $1.28 per share, with a dividend yield of 0.84%. TECH's next quarterly dividend payment will be made on Friday, May 25. Bio-Techne pays out 37.43% of its earnings out as a dividend.
Next Dividend:5/25/2018
Annual Dividend:$1.28
Dividend Yield:0.84%
Payout Ratio(s):37.43% (Trailing 12 Months of Earnings)
31.60% (Based on This Year's Estimates)
28.13% (Based on Next Year's Estimates)
25.36% (Based on Cash Flow)
Dividend Payments by Quarter for Bio-Techne (NASDAQ:TECH)

Bio-Techne (NASDAQ:TECH) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/3/2018quarterly$0.320.87%5/11/20185/14/20185/25/2018
2/7/2018quarterly$0.320.94%2/15/20182/16/20183/2/2018
10/31/2017Quarterly$0.321%11/9/201711/10/201711/24/2017
8/9/2017Quarterly$0.321.1%8/16/20178/18/20179/1/2017
5/2/2017quarterly$0.321.15%5/17/20175/19/20176/2/2017
2/7/2017quarterly$0.321.27%2/15/20172/17/20173/3/2017
11/1/2016Quarterly$0.3211/9/201611/14/201611/28/2016
8/17/2016quarterly$0.328/25/20168/29/20169/12/2016
5/3/2016quarterly$0.321.27%5/11/20165/13/20165/27/2016
2/2/2016quarterly$0.321.48%2/10/20162/12/20162/26/2016
10/29/2015quarterly$0.321.45%11/10/201511/13/201511/27/2015
8/6/2015quarterly$0.321.18%8/13/20158/17/20158/28/2015
5/5/2015quarterly$0.321.31%5/11/20155/15/20155/29/2015
2/3/2015quarterly$0.321.4%2/11/20152/13/20152/27/2015
10/30/2014quarterly$0.321.41%11/6/201411/10/201411/24/2014
8/11/2014quarterly$0.311.31%8/19/20148/21/20148/29/2014
4/28/2014quarterly$0.311.37%5/7/20145/9/20145/23/2014
2/4/2014quarterly$0.311.48%2/12/20142/14/20142/28/2014
10/31/2013quarterly$0.311.4%11/7/201311/12/201311/25/2013
8/6/2013quarterly$0.301.62%8/14/20138/16/20138/31/2013
4/30/2013quarterly$0.301.86%5/8/20135/10/20135/24/2013
2/5/2013quarterly$0.301.74%2/13/20132/15/20133/1/2013
(Data available from 1/1/2013 forward)

Insider Trades

Bio-Techne (NASDAQ TECH) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 3.40%
Institutional Ownership Percentage: 98.22%
Insider Trading History for Bio-Techne (NASDAQ:TECH)
Institutional Ownership by Quarter for Bio-Techne (NASDAQ:TECH)

Bio-Techne (NASDAQ TECH) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/13/2018Charles A DinarelloDirectorSell5,000$136.06$680,300.00View SEC Filing  
11/1/2017Robert V BaumgartnerDirectorSell5,000$130.18$650,900.0012,712View SEC Filing  
10/10/2017Roger C LucasDirectorSell100$121.96$12,196.00View SEC Filing  
9/8/2017Roger C LucasDirectorSell100$120.94$12,094.001,970View SEC Filing  
9/6/2017Karen A HolbrookDirectorSell1,059$121.73$128,912.07914View SEC Filing  
8/10/2017Roger C LucasDirectorSell100$114.30$11,430.002,070View SEC Filing  
7/10/2017Roger C LucasDirectorSell100$116.86$11,686.002,170View SEC Filing  
6/9/2017Roger C LucasDirectorSell100$113.62$11,362.002,270View SEC Filing  
5/31/2017Charles A DinarelloDirectorSell5,000$111.37$556,850.0012,473View SEC Filing  
5/25/2017Karen A HolbrookDirectorSell5,000$111.15$555,750.006,973View SEC Filing  
5/10/2017Roger C LucasDirectorSell100$110.59$11,059.003,429View SEC Filing  
4/10/2017Roger C LucasDirectorSell100$101.15$10,115.003,529View SEC Filing  
1/10/2017Roger C LucasDirectorSell100$103.57$10,357.003,829View SEC Filing  
11/29/2016Karen A HolbrookDirectorSell1,000$106.73$106,730.001,973View SEC Filing  
11/16/2016Roger C LucasDirectorSell100$105.75$10,575.004,029View SEC Filing  
9/21/2016Roger C LucasDirectorSell100$108.91$10,891.003,315View SEC Filing  
9/8/2016John L HigginsDirectorSell1,700$109.83$186,711.001,359View SEC Filing  
9/8/2016Kevin S. GouldSVPSell524$110.50$57,902.00View SEC Filing  
9/2/2016Robert V BaumgartnerDirectorSell6,467$107.17$693,068.398,446View SEC Filing  
8/24/2016Robert V BaumgartnerDirectorSell3,533$107.10$378,384.309,592View SEC Filing  
8/17/2016Roger C. LucasDirectorSell100$113.70$11,370.00View SEC Filing  
7/20/2016Roger C LucasDirectorSell100$111.03$11,103.003,615View SEC Filing  
6/15/2016Roger C LucasDirectorSell100$112.15$11,215.003,715View SEC Filing  
5/18/2016Roger C LucasDirectorSell100$102.53$10,253.003,815View SEC Filing  
5/9/2016Charles A DinarelloDirectorSell5,000$101.91$509,550.006,559View SEC Filing  
5/6/2016Roger C LucasDirectorSell500$100.24$50,120.003,915View SEC Filing  
4/20/2016Roger C LucasDirectorSell100$92.40$9,240.004,315View SEC Filing  
3/16/2016Roger C LucasDirectorSell100$92.90$9,290.004,415View SEC Filing  
2/5/2016Roger C. LucasDirectorSell5,000$83.68$418,400.004,515View SEC Filing  
8/13/2015Roger C LucasDirectorSell5,000$106.01$530,050.00View SEC Filing  
6/8/2015Randolph C SteerDirectorSell1,000$99.39$99,390.00View SEC Filing  
2/19/2015Howard V OconnellDirectorSell5,000$95.78$478,900.00View SEC Filing  
12/10/2014Karen A HolbrookDirectorSell1,000$92.40$92,400.00View SEC Filing  
12/9/2014Kevin J ReaganVPSell3,591$89.35$320,855.85View SEC Filing  
12/8/2014Charles A DinarelloDirectorSell3,000$90.44$271,320.00View SEC Filing  
8/14/2014Karen A HolbrookDirectorSell5,000$95.54$477,700.00View SEC Filing  
5/7/2014Howard OconnellDirectorSell5,000$91.00$455,000.001,000View SEC Filing  
3/4/2014Karen HolbrookDirectorSell5,000$89.83$449,150.001,000View SEC Filing  
2/27/2014Randolph SteerDirectorSell5,000$88.78$443,900.001,000View SEC Filing  
11/13/2013Randolph SteerDirectorSell15,000$86.20$1,293,000.001,000View SEC Filing  
11/8/2013Robert BaumgartnerDirectorSell10,000$87.00$870,000.004,000View SEC Filing  
11/4/2013Roger C LucasDirectorSell10,000$87.64$876,400.00View SEC Filing  
5/6/2013Howard V OconnellDirectorBuy2,361$65.00$153,465.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Bio-Techne (NASDAQ TECH) News Headlines

Source:
DateHeadline
Bio-Techne (TECH) Expected to Announce Quarterly Sales of $175.63 MillionBio-Techne (TECH) Expected to Announce Quarterly Sales of $175.63 Million
www.americanbankingnews.com - May 18 at 1:42 AM
 Analysts Anticipate Bio-Techne (TECH) Will Post Earnings of $1.28 Per Share Analysts Anticipate Bio-Techne (TECH) Will Post Earnings of $1.28 Per Share
www.americanbankingnews.com - May 16 at 11:12 PM
Contrasting Bio-Techne (TECH) & Mesoblast (MESO)Contrasting Bio-Techne (TECH) & Mesoblast (MESO)
www.americanbankingnews.com - May 14 at 10:15 AM
Bio-Techne To Present At The UBS Global Healthcare ConferenceBio-Techne To Present At The UBS Global Healthcare Conference
finance.yahoo.com - May 10 at 4:53 PM
Comparing Bio-Techne (TECH) and Pluristem Therapeutics (PSTI)Comparing Bio-Techne (TECH) and Pluristem Therapeutics (PSTI)
www.americanbankingnews.com - May 8 at 3:04 AM
When Should You Buy Bio-Techne Corporation (NASDAQ:TECH)?When Should You Buy Bio-Techne Corporation (NASDAQ:TECH)?
finance.yahoo.com - May 7 at 4:51 PM
Bio-Techne (TECH) Downgraded by Zacks Investment Research to "Hold"Bio-Techne (TECH) Downgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - May 4 at 12:07 AM
Bio-Techne (TECH) Price Target Cut to $165.00 by Analysts at Deutsche BankBio-Techne (TECH) Price Target Cut to $165.00 by Analysts at Deutsche Bank
www.americanbankingnews.com - May 3 at 11:03 PM
Leerink Swann Reiterates Outperform Rating for Bio-Techne (TECH)Leerink Swann Reiterates Outperform Rating for Bio-Techne (TECH)
www.americanbankingnews.com - May 3 at 8:35 PM
Bio-Techne (TECH) Declares Quarterly Dividend of $0.32Bio-Techne (TECH) Declares Quarterly Dividend of $0.32
www.americanbankingnews.com - May 3 at 5:16 PM
Edited Transcript of TECH earnings conference call or presentation 2-May-18 1:00pm GMTEdited Transcript of TECH earnings conference call or presentation 2-May-18 1:00pm GMT
finance.yahoo.com - May 3 at 9:05 AM
Bio-Techne (TECH) Q3 2018 Results - Earnings Call TranscriptBio-Techne (TECH) Q3 2018 Results - Earnings Call Transcript
seekingalpha.com - May 2 at 4:46 PM
Does Bio-Techne Corporation’s (NASDAQ:TECH) PE Ratio Warrant A Sell?Does Bio-Techne Corporation’s (NASDAQ:TECH) PE Ratio Warrant A Sell?
finance.yahoo.com - May 2 at 4:46 PM
Bio-Techne (TECH) Issues  Earnings ResultsBio-Techne (TECH) Issues Earnings Results
www.americanbankingnews.com - May 2 at 12:37 PM
BRIEF-Bio-Techne Q3 GAAP Earnings Per Share $0.52BRIEF-Bio-Techne Q3 GAAP Earnings Per Share $0.52
www.reuters.com - May 2 at 9:09 AM
Bio-Techne Corporation beats by $0.07, revenue in-lineBio-Techne Corporation beats by $0.07, revenue in-line
seekingalpha.com - May 2 at 9:09 AM
Bio-Techne Releases Third Quarter Fiscal 2018 ResultsBio-Techne Releases Third Quarter Fiscal 2018 Results
finance.yahoo.com - May 2 at 9:09 AM
Bio-Techne Corporation  beats by $0.07,  revenue in-lineBio-Techne Corporation  beats by $0.07, revenue in-line
seekingalpha.com - May 2 at 7:09 AM
Bio-Techne To Present At The Deutsche Bank 43rd Annual Health Care ConferenceBio-Techne To Present At The Deutsche Bank 43rd Annual Health Care Conference
finance.yahoo.com - May 1 at 4:36 PM
Zacks: Brokerages Anticipate Bio-Techne (TECH) Will Announce Quarterly Sales of $164.72 MillionZacks: Brokerages Anticipate Bio-Techne (TECH) Will Announce Quarterly Sales of $164.72 Million
www.americanbankingnews.com - May 1 at 3:35 AM
 Brokerages Expect Bio-Techne (TECH) Will Post Earnings of $1.14 Per Share Brokerages Expect Bio-Techne (TECH) Will Post Earnings of $1.14 Per Share
www.americanbankingnews.com - April 29 at 9:17 AM
Bio-Techne (TECH) Given Consensus Rating of "Buy" by AnalystsBio-Techne (TECH) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - April 29 at 8:04 AM
Bio-Techne Leads the Way in Scientific Support for Autophagy ResearchBio-Techne Leads the Way in Scientific Support for Autophagy Research
finance.yahoo.com - April 26 at 4:39 PM
Bio-Techne (TECH) Scheduled to Post Earnings on WednesdayBio-Techne (TECH) Scheduled to Post Earnings on Wednesday
www.americanbankingnews.com - April 25 at 2:38 AM
Bio-Techne Announces New Leadership AppointmentBio-Techne Announces New Leadership Appointment
finance.yahoo.com - April 24 at 4:54 PM
Bio-Techne (TECH) Coverage Initiated at Wells FargoBio-Techne (TECH) Coverage Initiated at Wells Fargo
www.americanbankingnews.com - April 18 at 1:56 PM
Analyzing Bio-Techne (TECH) & Osiris Therapeutics (OSIR)Analyzing Bio-Techne (TECH) & Osiris Therapeutics (OSIR)
www.americanbankingnews.com - April 16 at 7:07 PM
$164.72 Million in Sales Expected for Bio-Techne (TECH) This Quarter$164.72 Million in Sales Expected for Bio-Techne (TECH) This Quarter
www.americanbankingnews.com - April 14 at 3:51 AM
 Analysts Anticipate Bio-Techne (TECH) Will Announce Earnings of $1.14 Per Share Analysts Anticipate Bio-Techne (TECH) Will Announce Earnings of $1.14 Per Share
www.americanbankingnews.com - April 12 at 11:21 AM
BIO-TECHNE (TECH) Given Buy Rating at CitigroupBIO-TECHNE (TECH) Given Buy Rating at Citigroup
www.americanbankingnews.com - April 5 at 10:14 PM
BIO-TECHNE Corp (TECH) Given Average Rating of "Buy" by AnalystsBIO-TECHNE Corp (TECH) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - April 4 at 10:05 AM
BIO-TECHNE (TECH) Upgraded to Buy at ValuEngineBIO-TECHNE (TECH) Upgraded to Buy at ValuEngine
www.americanbankingnews.com - April 2 at 11:26 PM
BIO-TECHNE (TECH) Upgraded to "Buy" at BidaskClubBIO-TECHNE (TECH) Upgraded to "Buy" at BidaskClub
www.americanbankingnews.com - March 29 at 3:01 PM
 Analysts Anticipate BIO-TECHNE Corp (TECH) Will Post Quarterly Sales of $164.10 Million Analysts Anticipate BIO-TECHNE Corp (TECH) Will Post Quarterly Sales of $164.10 Million
www.americanbankingnews.com - March 28 at 8:09 AM
 Brokerages Anticipate BIO-TECHNE Corp (TECH) to Announce $1.15 EPS Brokerages Anticipate BIO-TECHNE Corp (TECH) to Announce $1.15 EPS
www.americanbankingnews.com - March 26 at 11:14 AM
3 Reasons Momentum Stock Investors Will Love Bio-Techne (TECH)3 Reasons Momentum Stock Investors Will Love Bio-Techne (TECH)
www.zacks.com - March 22 at 9:25 AM
Bio-Techne Expands RNAscope® ISH Automation - Facilitating Drug Discovery and DevelopmentBio-Techne Expands RNAscope® ISH Automation - Facilitating Drug Discovery and Development
www.prnewswire.com - March 21 at 1:24 PM
BidaskClub Upgrades BIO-TECHNE (TECH) to "Strong-Buy"BidaskClub Upgrades BIO-TECHNE (TECH) to "Strong-Buy"
www.americanbankingnews.com - March 16 at 10:28 PM
10 Growth Stocks for Long-Term Investors10 Growth Stocks for Long-Term Investors
finance.yahoo.com - March 15 at 9:04 AM
Bio-Techne Launches MimEX™ GI, an Accessible 3-D Cell Culturing Platform for the Gastrointestinal TractBio-Techne Launches MimEX™ GI, an Accessible 3-D Cell Culturing Platform for the Gastrointestinal Tract
finance.yahoo.com - March 14 at 6:02 PM
BIO-TECHNE Corp (TECH) Receives Average Rating of "Buy" from AnalystsBIO-TECHNE Corp (TECH) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - March 10 at 7:36 AM
BIO-TECHNE Corp (TECH) Expected to Post Earnings of $1.15 Per ShareBIO-TECHNE Corp (TECH) Expected to Post Earnings of $1.15 Per Share
www.americanbankingnews.com - March 9 at 5:58 AM
BIO-TECHNE Corp (TECH) Stake Decreased by Bank of New York Mellon CorpBIO-TECHNE Corp (TECH) Stake Decreased by Bank of New York Mellon Corp
www.americanbankingnews.com - March 6 at 4:54 AM
BIO-TECHNE Corp (TECH) Shares Bought by Arizona State Retirement SystemBIO-TECHNE Corp (TECH) Shares Bought by Arizona State Retirement System
www.americanbankingnews.com - March 3 at 4:22 AM
The Manufacturers Life Insurance Company  Grows Position in BIO-TECHNE Corp (TECH)The Manufacturers Life Insurance Company Grows Position in BIO-TECHNE Corp (TECH)
www.americanbankingnews.com - March 2 at 7:38 PM
BIO-TECHNE Corp (TECH) Position Raised by Snyder Capital Management L PBIO-TECHNE Corp (TECH) Position Raised by Snyder Capital Management L P
www.americanbankingnews.com - March 2 at 1:56 PM
Mackenzie Financial Corp Sells 143,295 Shares of BIO-TECHNE Corp (TECH)Mackenzie Financial Corp Sells 143,295 Shares of BIO-TECHNE Corp (TECH)
www.americanbankingnews.com - March 2 at 1:37 PM
BIO-TECHNE Corp (TECH) Shares Bought by California Public Employees Retirement SystemBIO-TECHNE Corp (TECH) Shares Bought by California Public Employees Retirement System
www.americanbankingnews.com - March 2 at 5:21 AM
BIO-TECHNE (TECH) PT Set at $163.00 by Deutsche BankBIO-TECHNE (TECH) PT Set at $163.00 by Deutsche Bank
www.americanbankingnews.com - March 1 at 7:15 PM
BIO-TECHNE Corp (TECH) Shares Sold by Rhumbline AdvisersBIO-TECHNE Corp (TECH) Shares Sold by Rhumbline Advisers
www.americanbankingnews.com - March 1 at 7:46 AM

SEC Filings

Bio-Techne (NASDAQ:TECH) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Bio-Techne (NASDAQ:TECH) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Bio-Techne (NASDAQ TECH) Stock Chart for Sunday, May, 20, 2018

Loading chart…

This page was last updated on 5/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.